Clinically, breast cancer represents a heterogeneous disease that is mainly grouped based on its hormone receptor (estrogen receptor [ER] or progesterone receptor [PR] positivity) and amplification of the ERBB2 gene (hereafter referred to as HER2+) (Sorlie 2004). Here, ERBB2 is linked to breast carcinoma.